Pediatric Migraine Studies
We collaborate with companies to bring the latest migraine clinical trials to the Cincinnati area! All studies involve medications that have already received FDA approval in adults with migraine and are now being evaluated in children under the age of 18 years. All study-related costs are fully covered by the sponsoring companies ensuring there are no out-of-pocket expenses for participants.
Abortive Studies
We’re currently enrolling children and teens ages 6 to 17 in research studies focused on treating migraines once they start. These “abortive” oral treatments are taken only when needed—not on a daily basis.
Right now, we’re studying two medications that are already FDA-approved for adults: Reyvow (lasmiditan) and Ubrelvy (ubrogepant), to see how well they work for pediatric patients who have fewer than 15 headache days per month.
All of our studies are officially listed on ClinicalTrials.gov, a trusted source for clinical research information.
Learn more about these studies:
Prevention Study
This study focuses on preventing migraines before they start. Unlike treatments taken during a migraine, preventive medications are taken on a regular schedule—some daily, some monthly, and some just a few times a year.
We’re currently enrolling teens ages 12 to 17 who experience 15 or more headache days per month.
This study is testing galcanezumab, a medication already approved for adults to help reduce the number
of migraine days. It’s given once a month as a small injection just under the skin (a subcutaneous
injection).
You can find full study details on ClinicalTrials.gov – NCT04616326